guest ::
| Home > Publications Database > Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease. > print |
| Home > Publications Database > Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease. > print |
| 001 | 164856 | ||
| 005 | 20230915090558.0 | ||
| 024 | 7 | _ | |a 10.1007/s12035-022-02891-7 |2 doi |
| 024 | 7 | _ | |a pmid:35716271 |2 pmid |
| 024 | 7 | _ | |a 0893-7648 |2 ISSN |
| 024 | 7 | _ | |a 1559-1182 |2 ISSN |
| 024 | 7 | _ | |a altmetric:129881721 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-01300 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Schmitz, Matthias |0 P:(DE-2719)9000287 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease. |
| 260 | _ | _ | |a Totowa, NJ |c 2022 |b Humana Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1661505075_607 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Biomarkers are becoming increasingly important for the differential diagnosis of neurodegenerative diseases. Previous observations indicated neurofilament light chain (NfL) as a potential blood-based biomarker for sporadic Creutzfeldt-Jakob disease (sCJD). Here, we investigated the stability, inter-assay/intra-assay variation and the regulation of NfL levels in CSF and plasma in a large cohort of sCJD patients by using a single-molecule array (SIMOA). We defined cutoffs for an accurate diagnosis and measured plasma NfL level in prion-infected mice models at different time points to identify the potential dynamics throughout the disease. Our analyses confirmed CSF and plasma NfL as stable and consistent marker for sCJD. Receiver operating characteristic (ROC) curve analysis showed an AUC of 0.92-0.93 to distinguish sCJD from control groups. Newly defined cutoffs revealed good diagnostic accuracies of CSF and plasma NfL, indicated by a sensitivity of 80-83.5% and a specificity of 87.4-91%. Studies on two humanized prion-infected mice lines (Tg340-PRNP 129MM and Tg361-PRNP 129VV) revealed increased plasma NfL levels in a late pre-clinical or very early clinical stage between 120-150 days post-inoculation. In conclusion, our work supports the potential use of CSF and plasma NfL as a very early biomarker in sCJD diagnostic with good diagnostic accuracies. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Biomarkers |2 Other |
| 650 | _ | 7 | |a Diagnostic |2 Other |
| 650 | _ | 7 | |a Neurofilament light chain |2 Other |
| 650 | _ | 7 | |a Plasma |2 Other |
| 650 | _ | 7 | |a Sporadic Creutzfeldt-Jakob disease |2 Other |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Biomarkers |2 MeSH |
| 650 | _ | 2 | |a Creutzfeldt-Jakob Syndrome: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Intermediate Filaments |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Neurofilament Proteins |2 MeSH |
| 650 | _ | 2 | |a Prions |2 MeSH |
| 650 | _ | 2 | |a tau Proteins |2 MeSH |
| 700 | 1 | _ | |a Canaslan, Sezgi |0 P:(DE-2719)9001944 |b 1 |e First author |u dzne |
| 700 | 1 | _ | |a Espinosa, Juan Carlos |b 2 |
| 700 | 1 | _ | |a Fernández-Borges, Natalia |b 3 |
| 700 | 1 | _ | |a Villar-Piqué, Anna |0 P:(DE-2719)9000327 |b 4 |u dzne |
| 700 | 1 | _ | |a Llorens, Franc |0 P:(DE-2719)2811280 |b 5 |u dzne |
| 700 | 1 | _ | |a Varges, Daniela |0 P:(DE-2719)9000324 |b 6 |u dzne |
| 700 | 1 | _ | |a Maass, Fabian |0 P:(DE-2719)9001334 |b 7 |u dzne |
| 700 | 1 | _ | |a Torres, Juan Maria |b 8 |
| 700 | 1 | _ | |a Hermann, Peter |0 P:(DE-2719)2812183 |b 9 |u dzne |
| 700 | 1 | _ | |a Zerr, Inga |0 P:(DE-2719)2000058 |b 10 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1007/s12035-022-02891-7 |0 PERI:(DE-600)2079384-4 |n 9 |p 1-9 |t Molecular neurobiology |v 59 |y 2022 |x 0893-7648 |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:164856 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9000287 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)9001944 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)9000327 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811280 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)9000324 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-2719)9001334 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2812183 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2000058 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL NEUROBIOL : 2021 |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-22 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOL NEUROBIOL : 2021 |d 2022-11-22 |
| 920 | 1 | _ | |0 I:(DE-2719)1440011-1 |k AG Zerr |l Translational Studies and Biomarkers |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)5000037 |k Ext UMG Zerr |l Ext UMG Zerr |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1440015 |k Clinical Dementia Research Göttingen |l Clinical Dementia Research Göttingen |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1440011-1 |
| 980 | _ | _ | |a I:(DE-2719)5000037 |
| 980 | _ | _ | |a I:(DE-2719)1440015 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|